Rosecliff Acquisition I Revenue Growth Rates (MDAI), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Rosecliff Acquisition Corp I  (NASDAQ: MDAI)
 

MDAI's Revenue Growth by Quarter and Year

Rosecliff Acquisition I's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

MDAI Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 3.52
1st Quarter March 4.09
FY 7.61

MDAIs Annual Revenue
Rosecliff Acquisition I's Revenue in the fiscal year 2026 $ 3.99 millions
Rosecliff Acquisition I's Revenue in the fiscal year 2025 $ 5.07 millions
Rosecliff Acquisition I's Revenue in the fiscal year 2024 $ 29.58 millions
Rosecliff Acquisition I's Revenue in the fiscal year 2023 $ 18.06 millions
Rosecliff Acquisition I's Revenue in the fiscal year 2022 $ 12.90 millions




MDAI Revenue second quarter 2026 Y/Y Growth Comment
Rosecliff Acquisition Corp I reported drop in Revenue in the second quarter 2026 by -53.63% to $ 3.52 millions, from the same quarter in 2025.
The fall in the second quarter 2026 Rosecliff Acquisition Corp I's Revenue compares unfavorably to the Company's average Revenue jump of 52.55%.

Looking into second quarter 2026 results within Medical Equipment & Supplies industry 179 other companies have achieved higher Revenue growth. While Rosecliff Acquisition Corp I' s Revenue meltdown of -53.63% ranks overall at the positon no. 3791 in the second quarter 2026.


MDAI Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - -49.33 % 76 % 224.43 %
3rd Quarter September - -19.91 % 24.61 % -32.45 %
2nd Quarter June -53.63 % 43.67 % 49.01 % -
1st Quarter March -49.94 % 137.5 % 549.06 % -84.5 %
FY   - 9.27 % 68.08 % -

Financial Statements
Rosecliff Acquisition I's second quarter 2026 Revenue $ 3.52 millions MDAI's Income Statement
Rosecliff Acquisition I's second quarter 2025 Revenue $ 7.60 millions Quarterly MDAI's Income Statement


MDAI Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - -25.25 % 18.17 % -16.34 %
3rd Quarter September - -33.29 % 19.66 % 43.1 %
2nd Quarter June -13.84 % -6.98 % 53.78 % 569.81 %
1st Quarter March 7.92 % 9.22 % -19.06 % -59.54 %
FY (Year on Year)   - 9.27 % 68.08 % -


Back to MDAI Growth rate Comparisons >> Back to MDAI Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #180
Healthcare Sector #526
Overall #3791

Revenue Y/Y Growth Statistics
High Average Low
554.49 % 52.55 % -84.63 %
 
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #180
Healthcare Sector #526
Overall #3791
Revenue Y/Y Growth Statistics
High Average Low
554.49 % 52.55 % -84.63 %
 

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Rosecliff Acquisition I's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
574.63 % 27.59 % -82.52 %
(Dec 31 2022)  


MDAI's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2026 Rosecliff Acquisition Corp I disclosed drop in Revenue from the first quarter by -13.84% to $ 3.52 millions, from $ 4.09 millions achived in the previous reporting period.

But that's not important problem, as Rosecliff Acquisition I's Revenue generally seem to plunge in this quarter.

Within Medical Equipment & Supplies industry 128 other companies have achieved higher Revenue quarter on quarter growth. While Rosecliff Acquisition I's Revenue growth quarter on quarter, overall rank is 3058.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #129
Healthcare Sector #394
Overall #3058
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #129
Healthcare Sector #394
Overall #3058
Revenue Q/Q Growth Statistics
High Average Low
574.63 % 27.59 % -82.52 %
(Dec 31 2022)  


MDAI's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2026 Rosecliff Acquisition Corp I disclosed drop in Revenue from the first quarter by -13.84% to $ 3.52 millions, from $ 4.09 millions achived in the previous reporting period.

But that's not important problem, as Rosecliff Acquisition I's Revenue generally seem to plunge in this quarter.

Within Medical Equipment & Supplies industry 128 other companies have achieved higher Revenue quarter on quarter growth. While Rosecliff Acquisition I's Revenue growth quarter on quarter, overall rank is 3058.


Rosecliff Acquisition I's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 16.47 $ 20.55 $ 20.55 $ 24.63 $ 28.32
Y / Y Revenue Growth (TTM) -44.33 % -24.64 % -24.64 % 9.33 % 46.71 %
Year on Year Revenue Growth Overall Ranking # 3500 # 4088 # 1432 # 326 #
Seqeuential Revenue Change (TTM) -19.86 % -16.59 % -16.59 % -13.02 % -4.26 %
Seq. Revenue Growth (TTM) Overall Ranking # 3500 # 4088 # 1432 # 326 #


Cumulative Revenue growth Comment
Rosecliff Acquisition I's cumulative 12 months Revenue continue to drop, but on the faster rate at -44.33% year on year, at Jun 30 2026 compare to the -24.64% decrease at Dec 31 2025. If the Rosecliff Acquisition I's fiscal year would end at Jun 30 2026, annual Revenue would be $16 millions.

In the Healthcare sector 94 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 3500, from total ranking in previous quarter at 4088.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 21
Healthcare Sector # 95
Overall # 371

Revenue TTM Y/Y Growth Statistics
High Average Low
90.72 %
 33.3 %
-44.33 %
(Sep 30 2023)  


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 148
Sector # 412
S&P 500 # 2972
Cumulative Revenue growth Comment
Rosecliff Acquisition I's cumulative 12 months Revenue continue to drop, but on the faster rate at -44.33% year on year, at Jun 30 2026 compare to the -24.64% decrease at Dec 31 2025. If the Rosecliff Acquisition I's fiscal year would end at Jun 30 2026, annual Revenue would be $16 millions.

In the Healthcare sector 94 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 3500, from total ranking in previous quarter at 4088.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 21
Healthcare Sector # 95
Overall # 371

Revenue TTM Y/Y Growth Statistics
High Average Low
90.72 %
33.3 %
-44.33 %
(Sep 30 2023)  


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 148
Sector # 412
S&P 500 # 2972




Other Revenue Growth
Medical Equipment & Supplies Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
MDAI's Revenue Growth Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Bio rad Laboratories Inc -0.05%$ -0.046 millions
Seer Inc -0.29%$ -0.289 millions
Dyadic International Inc -0.57%$ -0.568 millions
Teva Pharmaceutical Industries Limited-0.81%$ -0.814 millions
Aytu Biopharma Inc-0.91%$ -0.911 millions
Neuropace Inc -1.32%$ -1.323 millions
Ardent Health Inc -1.40%$ -1.400 millions
Sunshine Biopharma Inc -1.56%$ -1.557 millions
Pacific Biosciences Of California Inc -1.71%$ -1.706 millions
United Therapeutics Corporation-1.92%$ -1.916 millions
Orasure Technologies Inc-1.93%$ -1.930 millions
Pulmonx Corporation-1.93%$ -1.931 millions
Volitionrx Limited-1.97%$ -1.975 millions
Organon and Co -2.26%$ -2.258 millions
Airsculpt Technologies Inc -2.53%$ -2.527 millions
Charles River Laboratories International inc -2.72%$ -2.718 millions
Perrigo Company Plc-3.17%$ -3.171 millions
Zai Lab Limited-3.33%$ -3.333 millions
Vanda Pharmaceuticals Inc -3.92%$ -3.919 millions
Teladoc Health Inc -3.95%$ -3.952 millions
Dentsply Sirona Inc -4.06%$ -4.060 millions
Sanuwave Health Inc -4.18%$ -4.181 millions
Treace Medical Concepts Inc -4.24%$ -4.244 millions
Fortrea Holdings Inc -4.52%$ -4.519 millions
Positron Corporation-6.91%$ -6.907 millions
Standard Biotools Inc -7.05%$ -7.046 millions
Inspire Medical Systems inc -7.32%$ -7.316 millions
Adapthealth Corp -7.50%$ -7.505 millions
China Pharma Holdings Inc-7.55%$ -7.548 millions
Skinhealth Systems Inc -7.68%$ -7.680 millions


About Rosecliff Acquisition I Revenue Growth Rates (MDAI), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Spectral Ai Inc (CIK 1833498).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001213900-26-087764
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Spectral Ai Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.